Media

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

C4X Discovery's C4X3256 programme awarded $480k grant from the US National Institute on Drug Abuse (NIDA)

Grant awarded to investigate efficacy of C4X3256 in preclinical models of cocaine addiction, further demonstrating the efficacy of C4X3256 across broad addiction indications

24 July 2018 – C4X Discovery Holdings plc (AIM:C4XD), a pioneering drug discovery company, is pleased to announce that C4X Discovery’s C4X3256 programme has been awarded a grant from the National Institute on Drug Abuse (NIDA, a division of National Institute of Health (NIH)). The grant of approximately $480k will support the pre-clinical development of C4X3256 in cocaine use disorder, an additional addiction indication with high unmet need. Recently licensed to Indivior, C4X3256, an oral Orexin-1 receptor antagonist, has demonstrated an excellent safety profile and preclinical efficacy in models of nicotine addiction.

Wednesday, 04 July 2018

Board Changes

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

Board Changes

Eva-Lotta Allan appointed Non-Executive Chairman of the Board

Board further strengthened with the appointment of Natalie Walter

4 July 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Eva-Lotta Allan and Natalie Walter have been appointed as Non-Executive Chairman of the Board and Non-Executive Director respectively, with immediate effect.

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

Collaboration with e-Therapeutics to identify novel mechanisms for the treatment of Parkinson’s Disease

1 May 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a joint research collaboration with e-Therapeutics plc (AIM: ETX) to identify novel mechanistic insights into Parkinson’s Disease (PD). The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3® novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will use the outputs from C4XD’s Taxonomy3® genetic analysis of PD and apply an NDD approach to identify novel intervention strategies which it is expected will lead to new approaches for the treatment of PD.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU.

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

Interim results for the six months ended 31 January 2018

12 April 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its interim results for the six months ended 31 January 2018.

C4X Discovery Holdings plc

("C4XD" or the "Company")

C4X Discovery signs licensing agreement with Indivior for addiction programme worth up to $294m

C4XD receives $10 million upfront, potential milestones totalling $284 million plus royalties

29 March 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that it has signed a licensing agreement with Indivior UK Limited (LON: INDV, "Indivior") to further develop and commercialise C4XD’s oral Orexin-1 receptor antagonist ("C4X3256") for the treatment of addiction. C4X3256 aims to treat addiction by targeting the "craving" process itself and, therefore, can be applied across a broad range of substance use disorders. The treatment of addiction represents a substantial area of unmet medical need, forecast to be worth an estimated $13 billion per annum in 20181.

C4X Discovery Holdings plc

("C4XD" or the "Company")

Full year results for the year ended 31 July 2017

14 December 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its full year results for the year ended 31 July 2017.

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

C4XD presents data on its lead addiction programme: Orexin-1 antagonist

Programme demonstrates potential application across a broad range of substance use disorders

13 November 2017 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, presented new pre-clinical data on its Orexin-1 antagonist programme at Neuroscience 2017 on 11th November 2017 in Washington, DC.

Tuesday, 05 September 2017

Business Update

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

Business Update

5 September 2017 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today provides an update on the Drug Discovery Engine and portfolio progress.